Bio-Techne (TECH) Enhances Industry Presence with Key Upcoming Healthcare Conferences

Bio-Techne Strengthens Industry Presence with Upcoming Conferences

Bio-Techne Corporation, a prominent player in the life sciences sector, actively showcases its commitment to innovation and collaboration through participation in key healthcare conferences in September 2025. The company is set to present at the Wells Fargo Healthcare Conference on September 3, followed by the Baird Global Healthcare Conference on September 9, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10. These events provide Bio-Techne with an opportunity to connect with investors and industry stakeholders, discussing their latest advancements in research tools and bioactive reagents that are vital for both scientific exploration and clinical diagnostics.

The presentations highlight Bio-Techne's extensive portfolio, which includes hundreds of thousands of products designed to facilitate drug discovery and enhance clinical testing accuracy. With a reported net sales figure exceeding $1.2 billion for fiscal 2025, the company continues to demonstrate robust growth and influence within the biotech landscape. Their innovative solutions play a crucial role in advancing scientific investigations into biological processes and the progression of diseases, positioning Bio-Techne as a leader in the life sciences community.

As Bio-Techne prepares for these significant events, the company emphasizes the importance of transparency and engagement with investors. Live webcasts of the presentations will be accessible through the Investor Relations page on their website, ensuring that stakeholders remain informed and connected. This commitment to open communication reflects Bio-Techne's dedication to fostering relationships and promoting understanding of their impactful contributions to healthcare and life sciences.

In addition to its conference participation, Bio-Techne maintains an active online presence, encouraging stakeholders to explore its offerings through various social media platforms such as LinkedIn, X, and YouTube. With a dedicated team of approximately 3,100 employees worldwide, the company is well-equipped to support ongoing advancements in drug discovery and clinical diagnostics, further solidifying its role as a vital resource in the life sciences industry.

For inquiries related to the upcoming investor presentations, David Clair, Vice President of Investor Relations and Corporate Development, is available to provide assistance, highlighting Bio-Techne's commitment to investor engagement and communication. As the company continues to expand its influence and innovation, these conferences serve as pivotal moments for sharing insights and fostering collaboration within the healthcare sector.